Zentalis Pharmaceuticals (ZNTL) said Thursday the US Food and Drug Administration granted fast track designation to the company's azenosertib drug candidate to treat several forms of platinum-resistant gynecological cancers in patients.
Fast track designation by the US Food and Drug Administration is intended to support and accelerate development of medicines and therapies showing a strong potential to treat serious medical conditions often lacking effective treatments at this time, the company said.
The FDA temporarily placed a partial hold on clinical testing of azenosertib as a monotherapy for ovarian, fallopian tube or primary peritoneal cancers in June 2024 following the death of two trial participants due to suspected blood-related infections. The agency lifted its hold on Sept. 16.
Zentalis also said Thursday it will present top-line data from those studies as well as another trial of azenosertib in combination with Pfizer's (PFE) encorafenib and Eli Lilly's (LLY) cetuximab chemotherapies in patients with metastatic colorectal cancer.
Price: 2.78, Change: -0.21, Percent Change: -7.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.